Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
暂无分享,去创建一个
Junhua Li | Judong Shen | M. Wilcox | Hailong Zhao | M. Dorr | D. Guris | I. Poxton | P. Shaw | Zhen Zeng
[1] D. Gerding,et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] E. Dubberke,et al. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] D. Gerding,et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection , 2017, New England Journal of Medicine.
[4] E. Dubberke,et al. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach , 2016, BMC Infectious Diseases.
[5] L. Valiquette,et al. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] T. Louie,et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Kristin E. Burke,et al. Clostridium difficile Infection: A Worldwide Disease , 2014, Gut and liver.
[8] T. Peto,et al. Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile , 2013, The Journal of infectious diseases.
[9] Daniel J. Wilson,et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. , 2013, The New England journal of medicine.
[10] D. Gerding,et al. Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[12] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[13] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[14] J. Mossong,et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[15] F. Barbut,et al. Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.
[16] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .